Reference to what was published in the news under “Avigan® Approved for COVID-19 Treatment in Malaysia”, Agility would like to announce that the Malaysian Ministry of Health’s Drug Control Authority has approved Avigan® for use in treatment of COVID-19 patients.
Earlier this year, Global Response Aid (GRA), an affiliate of Agility, and Dr. Reddy’s Laboratories signed an agreement for exclusive global production, distribution and commercialization of the drug with its developer, FujiFilm Toyama Chemical.
Agility cannot assess the financial impact at the moment.
Get real-time air & ocean freight quotes and access to a powerful dashboard.
Kuwait-based Agility Logistics Parks customers can log-on to view contracts and make payments.
UK MOD personnel can log-in to the GRMS portal to schedule household relocation shipments.
Get real-time air & ocean freight quotes and access to a powerful dashboard.
Kuwait-based Agility Logistics Parks customers can log-on to view contracts and make payments.
UK MOD personnel can log-in to the GRMS portal to schedule household relocation shipments.
Agility’s 2025 Kuwait Community Initiatives to Support 5,000+ people
Learn More
Download Report
Get real-time air & ocean freight quotes and access to a powerful dashboard.
Kuwait-based Agility Logistics Parks customers can log-on to view contracts and make payments.
UK MOD personnel can log-in to the GRMS portal to schedule household relocation shipments.
Get real-time air & ocean freight quotes and access to a powerful dashboard.
Kuwait-based Agility Logistics Parks customers can log-on to view contracts and make payments.
UK MOD personnel can log-in to the GRMS portal to schedule household relocation shipments.
Commenting on published news
Reference to what was published in the news under “Avigan® Approved for COVID-19 Treatment in Malaysia”, Agility would like to announce that the Malaysian Ministry of Health’s Drug Control Authority has approved Avigan® for use in treatment of COVID-19 patients.
Earlier this year, Global Response Aid (GRA), an affiliate of Agility, and Dr. Reddy’s Laboratories signed an agreement for exclusive global production, distribution and commercialization of the drug with its developer, FujiFilm Toyama Chemical.
Agility cannot assess the financial impact at the moment.
Sincerely,
Investor Relations Team
Latest Financial News
July 3, 2025
Disclosure Related to Legal Cases
June 29, 2025
Supplemental Disclosure related to a Short-Term Facility
June 29, 2025
Agility’s In-Kind Dividends
June 23, 2025
Results of the Investors Call
June 23, 2025
Confirmation of Corporate Actions Schedule
June 19, 2025
Agility’s Investor Webcast